Integra Lifesciences Holdings (IART) Operating Expenses (2009 - 2026)

Integra Lifesciences Holdings has disclosed Operating Expenses across 18 years of filings, most recently posting $380.4 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $380.4 million, down 4.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 30.68% YoY), and the FY2025 annual result was $2.1 billion, up 34.54% from the prior year.
• Operating Expenses came in at $380.4 million for Q1 2026 at Integra Lifesciences Holdings, down from $411.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $928.3 million in Q2 2025 to a low of $320.1 million in Q3 2022.
• The 5-year median for Operating Expenses is $368.8 million (2023), against an average of $402.4 million.
• Across the five-year window, Operating Expenses retreated 4.93% in 2022 and surged 120.39% in 2025, its largest moves.
• Integra Lifesciences Holdings' Operating Expenses stood at $330.2 million in 2022, then rose by 9.33% to $361.0 million in 2023, then increased by 12.75% to $407.0 million in 2024, then advanced by 1.2% to $411.9 million in 2025, then slipped by 7.63% to $380.4 million in 2026.
• The last three Operating Expenses figures came in at $380.4 million (Q1 2026), $411.9 million (Q4 2025), and $390.3 million (Q3 2025), per Business Quant data.